{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976450",
  "id": "02976450",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250804",
  "time": "0934",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mhjx83rpyzls.pdf",
  "summary": "**Capital Raising Announcement:**  \n- **Structure:** Two-tranche Placement ($3.5M total) with free attaching listed options (1:1 ratio).  \n- **Issue Price:** $0.015/share (10% discount to 10-day VWAP).  \n- **Use of Funds:** HER2 Breast Cancer Phase 2 trial initiation, prostate/ovarian cancer Phase 1 programs, FDA IND submission, IP filings, and AI/MRI platform development.  \n- **Key Dates:**  \n  - **Tranche 1 Settlement:** 5 August 2025.  \n  - **Tranche 1 Trading Starts:** 6 August 2025.  \n  - **EGM (Tranche 2 Approval):** 18 September 2025.  \n  - **Tranche 2 Settlement & Trading:** 19 & 22 September 2025.  \n- **Attachments:** Options (IBXO terms: $0.04 exercise, expiry 13 Dec 2027).  \n- **Broker Fee:** 6% of proceeds; 26.25M unlisted options issued to CPS Capital.  \n- **Director Participation:** $150K subject to EGM approval.  \n\n*Omitted: Background on technology, leadership quotes, routine legal/timetable disclaimers.*",
  "usage": {
    "prompt_tokens": 1802,
    "completion_tokens": 275,
    "total_tokens": 2077,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-03T23:56:04.691201"
}